Dementia Treatment Market Report 2026

The dementia treatment market size has grown strongly in recent years. It will grow from $19.95 billion in 2025 to $21.81 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to aging global population, rising prevalence of alzheimer’s disease, increased diagnosis rates, long-term use of cholinesterase inhibitors, expansion of geriatric healthcare services.

The dementia treatment market size is expected to see strong growth in the next few years. It will grow to $31.13 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growth in precision medicine approaches, rising demand for disease-modifying therapies, increased investment in neurodegenerative research, expanding homecare treatment models, improved early diagnostic capabilities. Major trends in the forecast period include increasing adoption of combination drug therapies, growing focus on early-stage dementia intervention, rising use of symptom management treatments, expansion of non-pharmacological care approaches, increased emphasis on personalized treatment plans.

The increasing prevalence of neurodegenerative disorders is expected to drive growth in the dementia treatment market in the coming years. Neurodegenerative disorders are characterized by the progressive degeneration and loss of nerve cells, resulting in gradual impairments in movement, cognition, or both. This rise is largely attributed to the aging population, as longer life expectancy heightens the risk of developing age-related conditions such as Alzheimer’s and Parkinson’s disease, with age being the primary contributing factor. Understanding these disorders supports dementia treatment by enabling accurate diagnoses and targeted therapies, allowing for a more personalized and effective management of symptoms. For instance, in April 2024, according to the Alzheimer's Association, a US-based nonprofit health organization, approximately 6.9 million Americans aged 65 and older were living with Alzheimer’s dementia, a number projected to nearly double to 13.8 million by 2060. Therefore, the growing prevalence of neurodegenerative disorders is fueling the growth of the dementia treatment market.

Major companies operating in the dementia treatment market are focusing on developing technologically advanced solutions, such as virtual reality (VR) training programs, to recreate complex and varied scenarios. Virtual reality training programs are immersive, computer-generated simulations that enable individuals to practice and enhance skills within a controlled, interactive, and realistic virtual environment. For instance, in September 2024, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, partnered with Jolly Good Inc., a Japan-based medical technology company, to launch FACEDUO, a virtual reality training program for dementia care. This interactive VR tool, guided by medical experts, assists caregivers, including family members, in understanding the emotions and behaviors of people living with dementia. By simulating real-life situations, the program helps caregivers respond more effectively to the unique needs of dementia patients, aiming to enhance caregiving skills and foster empathy for improved support.

In April 2024, Rippl, a US-based provider of dementia-focused specialty care, acquired Kinto for an undisclosed amount. This acquisition aims to accelerate the growth of Rippl’s dementia care platform by integrating artificial intelligence (AI)-driven solutions to enhance patient care. Kinto is a US-based healthcare company specializing in AI solutions for dementia care.

Major companies operating in the dementia treatment market are Biogen Inc., Eisai Co. Ltd., Eli Lilly and Company, Roche Holding AG, AbbVie Inc., Sanofi S.A., Amgen Inc., Merz Pharmaceuticals GmbH, Acadia Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Otsuka Pharmaceutical Co. Ltd., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Cerevance Inc., AviadoBio Ltd., Cassava Sciences Inc., Anavex Life Sciences Corp.

North America was the largest region in the dementia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dementia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dementia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the dementia treatment market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and formulation excipients used in cognitive and neurological medications. These impacts have been most pronounced in branded and combination therapy segments, particularly in North America and Europe where global API sourcing is common. Asia-Pacific manufacturers have faced supply chain disruptions and pricing pressure. However, tariffs have encouraged local manufacturing of generic dementia drugs and strengthened regional supply resilience.

The dementia treatment market research report is one of a series of new reports that provides dementia treatment market statistics, including dementia treatment industry global market size, regional shares, competitors with a dementia treatment market share, detailed dementia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the dementia treatment industry. This dementia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dementia treatment involves a combination of medical, psychological, and supportive strategies aimed at managing symptoms and slowing the progression of the condition, which is characterized by memory loss, cognitive decline, and difficulties with reasoning. Early detection allows for more effective intervention and planning for long-term care. Personalized treatment approaches based on the type and stage of dementia can enhance the quality of life for affected individuals.

The main types of dementia treatment include antipsychotics, cholinesterase inhibitors, memantine, and others. Antipsychotic medications are used to manage behavioral and psychological symptoms such as aggression, agitation, and hallucinations. They are indicated for conditions including Alzheimer’s disease dementia, vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson’s disease dementia, and others. These drugs can be administered orally, via transdermal patches, or by injection, and are used for mild, moderate, and severe dementia. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The dementia treatment market consists of revenues earned by entities by providing services such as medication management, cognitive therapy and stimulation, and behavioral and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. The dementia treatment market also includes sales of memory-enhancing medications, nutritional supplements, cognitive stimulation tools, and medical alert systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.